Key Takeaways
- Director David Wells acquired 48,400 shares of HIMS for approximately $1.2 million, marking his first significant open-market transaction in nearly five years.
- Following the disclosure, HIMS shares climbed approximately 6.8% to reach $25.46.
- Year-to-date, HIMS has declined over 21% in 2026, lagging significantly behind the S&P 500’s 9.9% increase.
- Shares tumbled more than 14% in early May following disappointing first-quarter earnings results.
- The company is transitioning away from compounded GLP-1 medications as original manufacturers Novo Nordisk and Eli Lilly restore their market presence.
David Wells, a board member at Hims & Hers Health (HIMS), acquired 48,400 shares on Tuesday through open-market transactions priced between $24.19 and $24.25 per share. The total investment amounted to approximately $1.2 million. This purchase increased Wells’ overall position to 224,400 shares and represented his first open-market acquisition since August 2021.
Hims & Hers Health, Inc., HIMS
The transaction caught investor attention. HIMS shares rallied approximately 6.8% to $25.46 during the trading session following the filing disclosure, with market participants interpreting the insider purchase as a bullish signal.
Wells, who previously served as Chief Financial Officer at Netflix and joined the Hims board in 2020, had been exclusively selling shares in recent years. He divested 260,000 shares in February 2024 and an additional 40,000 shares in November of that year. His decision to switch from seller to buyer after nearly five years of disposals captured significant market interest.
Challenges Facing HIMS in 2026
Shares of HIMS have fallen more than 21% year-to-date, substantially underperforming the S&P 500’s 9.9% advance during the same period. This performance gap highlights the mounting challenges facing the telehealth company.
Earlier this month, the stock experienced a sharp decline of over 14% following the release of first-quarter financial results. The company reported a quarterly loss alongside revenue figures that fell short of analyst projections—disappointing outcomes that rattled investor confidence.
A primary source of concern centers on the company’s GLP-1 weight-loss medication segment. Hims experienced rapid expansion by providing lower-cost compounded alternatives during periods when branded treatments from Novo Nordisk and Eli Lilly faced supply constraints. However, as availability of the original branded medications has normalized, Novo and Lilly have begun recapturing their market positions.
Strategic Shift From Compounded Weight-Loss Drugs
In March, Hims announced a partnership to distribute Novo Nordisk’s branded weight-loss pharmaceutical directly via its digital platform, effectively substituting the compounded versions it had previously offered. Subsequently in April, the company expanded its platform capabilities to enable healthcare providers to issue prescriptions that could be fulfilled through independent pharmacy networks, including LillyDirect.
This represents a substantial strategic realignment. Compounded GLP-1 treatments had evolved into a central component of Hims’ value proposition for both consumers and shareholders. Maintaining revenue momentum while transitioning away from this category presents a critical test for the organization.
Separately, Wells was granted 957 restricted stock units on May 20 as part of routine director compensation arrangements.
As of the Wednesday closing bell, HIMS traded at $25.46, reflecting a 6.8% gain for the session following the disclosure of Wells’ purchase.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
